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a b s t r a c t
Carbamazepine (CBZ) is an active pharmaceutical ingredient used in the treatment of epilepsy that can
form at least 5 polymorphic forms. Metastable form IV was originally discovered from crystallization
with polymer additives; however, it has not been observed from subsequent solvent-only crystallization
efforts. This work reports the reproducible formation of phase pure crystalline form IV by spray drying of
methanolic CBZ solution. Characterization of the material was carried out using diffraction, scanning
electron microscopy, and differential scanning calorimetry. In situ Raman spectroscopy was used to
monitor the spray-dried product during the spray drying process. This work demonstrates that spray
drying provides a robust method for the production of form IV CBZ, and the combination of high su-
persaturation and rapid solid isolation from solution overcomes the apparent limitation of more tradi-
tional solution crystallization approaches to produce metastable crystalline forms.
© 2017 The Authors. Published by Elsevier Inc. on behalf of the American Pharmacists Association®. This
is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Introduction
Active pharmaceutical ingredients (APIs) and formulated
dosage forms are largely produced using traditional batch
manufacturing methods. However, there is increasing interest in
exploiting the potential advantages of continuous processing that
include improved consistency, process efﬁciency, and reduced
cost of goods in the manufacture of pharmaceuticals.1 Spray
drying enables particle formation and isolation in a single
continuous operation and so presents the opportunity to simplify
multiple batch operations into a single step. The present study,
therefore, investigates particle formation of the API carbamaze-
pine (CBZ) in a spray dryer.
Many APIs exhibit multiple polymorphic forms that can display
different physical attributes.2 This range of accessible properties
can lead to variability during processing and ultimately in use
through changes in stability, ﬂow, shape, aerodynamic perfor-
mance, solubility, dissolution, or bioavailability.3 Consequently,
there is a requirement to understand and control the polymorphic
forms that are used in products. Although capabilities for ab initio
crystal structure prediction of polymorphs from molecular struc-
ture have developed considerably in recent years,4 they not yet
routinely applicable to gain the complexity of typical APIs. There-
fore, extensive experimental investigations are still largely required
to deﬁne the range of potential polymorphic structures, their
relative thermodynamic experimental stabilities, and the condi-
tions under which they can be formed.5
CBZ is an API which is used in the treatment of epilepsy and
trigeminal neuralgia.6,7 CBZ has a low water solubility (<200 mg/
mL)6 and falls within class II of the Biopharmaceutical Classiﬁca-
tion System and can show dissolution-limited absorption.8 The
solid-state forms of CBZ have been widely studied, and it has
been reported in 5 different polymorphic forms, CBZ I, II, III, IV,9
and V10 in addition to a large number of solvated,11 co-
crystalline forms,12,13 salts,14 and nanocrystalline forms.15 The
thermodynamically stable form at room temperature is the
monoclinic CBZ III.16
Polymorphism of CBZ has been widely investigated using
different screening approaches,16,17 theoretical analysis,18 and
crystal structure prediction.12 CBZ IV was ﬁrst obtained by re-
crystallization from methanol solution in the presence of hydrox-
ypropylcellulose9 and was subsequently reported using polymer
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heteronucleation.19 However, subsequent attempts to obtain form
IV from solution, including multiple solvent screens12 and single
solvent screens,16 did not produce any evidence of CBZ IV. This was
explained due to the absence of polymer additives in these studies.
Notably, Kiporous et al.20,21 in a study of analytical techniques for
polymorphic mixtures stated CBZ IV used in that study was pro-
duced by spray drying from methanol. No further detail on the
method was provided or mechanism proposed for the occurrence
of CBZ IV.
Spray drying is an important technique for pharmaceutical
manufacturing and is generally used to isolate from a suspension
through conversion of a liquid or solution stream into a solid
powder through controlled, rapid evaporation of solvent or liquid
by a heated drying gas.22 It is well known for the formation of
amorphous solids in pharmaceuticals and food areas23 and being
applied to a range of particle engineering applications.24,25 How-
ever, it has also been demonstrated for the production of crystalline
particles, such as spray drying of the API salbutamol sulfate,26
excipient mannitol crystals,27 and co-crystals of CBZ and
nicotinamide.28
The present study seeks to investigate the formation of form IV
CBZ during spray drying and the potential of polymorph control.25
Herewe report a robust and reproducible method for production of
CBZ IV that does not require polymer additives. The application of
in situ Raman monitoring is also demonstrated.
Materials and Methods
Materials
CBZ III was sourced from Molekula and methanol (high-per-
formance liquid chromatography grade, 99.5%) from Sigma-
Aldrich.
Spray Drying Method
CBZ solutions were spray dried using a Büchi B-290 Mini Spray
Dryer coupled with the Büchi Inert Loop B-295 (Büchi Labor-
technik AG, Flawil, Switzerland) and conﬁgured with a high-
performance cyclone. The dryer was operated in co-current
closed mode with nitrogen as the drying gas. The starting
composition of solutions to be introduced into the dryer was 10.4
g/L CBZ in methanol at room temperature. The spray dryer pa-
rameters used to obtain a dry powder were aspirator rate 100%,
inlet temperature ¼ 393.15 K, outlet temperature ¼
338.15e348.15 K, pump percentage ¼ 10%, spray gas ¼ 7 bar
pressure, and spray gas rate operated between 439 and 667 L/h
(at standard temperature and pressure).
X-Ray Powder Diffraction
All spray-dried powders were analyzed using X-ray powder
diffraction (XRPD). Samples were analyzed using transmission foil
XRPD data collected on a Bruker AXS D8-Advance transmission
diffractometer equipped with q/q geometry, primary mono-
chromated radiation (Cu Ka1, l ¼ 1.54056 Å), a Vantec 1D position-
sensitive detector, and an automated sample stage.29 Samples were
mounted on a 28 position sample plate supported on a polyimide
(Kapton, 7.5 mm thickness) ﬁlm. Data were collected from each
sample in the range 4-35 2qwith a 0.015 2q step size and 1 s/step
count time. Samples were oscillated 0.5 mm in the xey plane at a
speed of 0.3 mm/s throughout data collection. Resultant CBZ form
was identiﬁed by standard procedures including pattern matching
and Pawley30 reﬁnement.
Scanning Electron Microscopy
The morphology and particle size of spray-dried samples were
imaged using a Hitachi SU6600 Analytical VP FEG-SEM. Samples
were mounted and analyzed at 5 kV.
Particle Sizing
Particle size and particle size distributions of the spray-dried
samples were analyzed using a Malvern Morphologi G3 instru-
ment. This technique integrates compressed air dispersion with
automated microscopy to image and collect size and shape data for
the sample particle population. The 3-dimensional particles are
imaged in 2 dimensions. The diameter of a circle is then calculated
with equal area to the projected area of the particle known as the
circle equivalent (CE) diameter.31
Thermal Analysis
Differential scanning calorimetry (DSC) of samples was carried
out in a Netzsch STA 449 C instrument. Samples were placed in a
10-mL Al crucible with pierced lid to allow loss of water vapor. The
samples were analyzed using a heating rate of 10 K/min from
293.15 to 493.15 K.
Raman
Raman spectra were also collected from samples using ofﬂine
measurements and from the spray drier using a Kaiser RXN1
Raman spectrometer equipped with PhAT probe. The PhAT probe
uses a class 3 laser beam with a 6-mm spot size and enables
noninvasive measurement of Raman spectra from solids.32 For the
ofﬂine measurement, a glass vial containing sample was analyzed.
For the online measurement, the PhAT probe was positioned at the
collection vessel of the high-performance cyclone to measure the
ﬁnal dried product emerging from the process.
Results and Discussion
CBZ IV
The spray drying process conditions successfully produced a dry,
crystalline CBZ sample. The sample was identiﬁed as CBZ IV by
comparison of the experimental XRPD data with calculated XRPD
reference patterns for forms I-IV (Fig. 1). The data comprised sharp
diffraction peaks with no evidence of an elevated background
scattering that might indicate amorphous content. This result was
conﬁrmed through analysis using a Pawley-type ﬁt30 (Fig. 2).
The Pawley-type ﬁt to the data from the spray-dried sample was
carried out in the TOPAS software package.33 The ﬁt to the data is
very good, and the reﬁned, room temperature lattice parameters
obtained were a ¼ 26.432(2)Å, b ¼ 7.0360(6)Å, c ¼ 13.9044(16)Å,
and b ¼ 109.570(7), space group C2/c (cf. the reported values from
the single crystal study a ¼ 26.609(4), b ¼ 6.927(1), c ¼ 13.957(2),
and b ¼ 109.7(1), CSD REFCODE: CBMZPN12).9 There is no evi-
dence of any diffraction peaks from the sample that are not accu-
rately described by the structure of CBZ IV, conﬁrming the phase
purity, to the limit of detection for XRPD, of the spray-dried
sample.20,21
To understand process robustness of the spray dryer with
respect to CBZ IV formation, 3 process parameters were varied,
speciﬁcally, inlet temperature and feed pump rate (conditions 1-3)
and solvent (condition 4; Table 1). Conditions were selected that
may be expected to effect the rate of drying and initial nucleation
conditions within the range required to obtain a dry powder.
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Noninvasive in situ Raman spectroscopy was used to obtain real-
time measurements during each of the experiments. To investigate
the impact of the different parameters, a comparison of the resul-
tant Raman spectra along with an ofﬂine reference of CBZ IV is
shown in Figure 3.
The spectra collected from the spray-dried samples produced
from each conditions 1-4 (Table 1) show some differences in
baseline and signal-to-noise; however, the characteristic Raman
bands show a direct correspondence with the form IV Raman
reference spectrum. No peaks from alternative CBZ forms were
observed. The formation of CBZ IV by spray drying is highly repro-
ducible and relatively insensitive to limited changes in the process
conditions and a change of solvent from methanol to ethanol.
Samples of spray-dried CBZ IV were characterized using scan-
ning electron microscopy (SEM) (Fig. 4), particle sizing (Fig. 5), and
DSC (Supplementary Data). SEM shows particles with diameters in
the between <1 and 5 microns consistent with expectation from
the Büchi mini dryer.34 The particles are reasonably isometric and
show clearly deﬁned facets with some evidence of agglomeration.
In contrast, Lang et al.9 reported the morphology of form IV crystals
to be “plate like.”
Particle size and size distribution of spray-dried material were
measured using a Malvern Morphologi G3. CE diameter, aspect
ratio, and high sensitivity circularity were determined against the
volume distribution (Fig. 5).
The CE diameter illustrates a multimodal distribution of particle
sizes with a mean size of 5.5 mmwith evidence of large aggregates,
which is supported by the SEM images.
DSC analysis of the spray-dried samples conﬁrms the expected
thermal behavior of CBZ IV (see Supplementary Data) and show
good correspondence to the previously reported thermal analysis of
anhydrous CBZ polymorphs.19 Spray-dried samples were shown by
XRPD to be stable for at least 3 months at 293.15 K (see
Supplementary Data).
CBZ IV Solution-Mediated Transformation
Although spray drying of methanol and ethanol CBZ solutions
yields form IV, previous crystallization studies that have included
recrystallization from methanol solution have not reproduced this
metastable form.9,12,16,19 This is despite the inclusion of conditions
conducive to rapid precipitation that may be expected to favor
metastable forms.
The original report of CBZ IV19 produced the polymorph by slow
evaporative recrystallization from methanol solution in the pres-
ence of hydroxypropylcellulose at room temperature. Getsoian
et al.16 investigated CBZ polymorphs using a single-solvent screen
and observed CBZ I, II, and III through temperature and supersat-
uration control. However, attempts to obtain reference samples of
form IV by recrystallization directly from solution were unsuc-
cessful, and a sample was ultimately obtained by de-solvation of a
solvated form. It has been concluded that12 proposed form IV
requires polymers to act as templates and their absence prevents
crystallization of CBZ IV directly from solution. Electrospray
crystallization from methanol solution produced amorphous
nanoparticles that transformed to CBZ III or I depending on post-
solidiﬁcation annealing conditions.35 This suggests under the
conditions used in electrospray, solidiﬁcation occurs so rapidly that
nucleation of crystals is predicted.
The reported inconsistency of solution crystallization studies to
reproduce CBZ IV is notable. This could indicate that form IV does
not nucleate directly from solution and requires the presence of an
additive that either templates CBZ IV or inhibits the nucleation of
competing forms. However, the occurrence of CBZ IV from spray
drying of CBZ solution does not support this conclusion. The rela-
tive thermodynamic stabilities of CBZ I, II, III, and IV have been
reported as III > I > IV > II based on thermal analysis.19 Thus, under
solution conditions where CBZ IV is nucleated, the metastable form
would be expected to transform to themore stable polymorphs CBZ
I or III through solution-mediated transformation.36 It is, therefore,
proposed in the spray dryer that the combination of a high rate of
supersaturation from rapid evaporation at elevated temperature
promotes the formation of metastable CBZ IV and the rapid isola-
tion of the metastable polymorph prohibits subsequent solution-
mediated transformation, enabling recovery of solid CBZ IV.
Figure 2. Pawley ﬁt of the data from the spray-dried CBZ sample. Observed proﬁle (o),
calculated proﬁle (), and difference plot (Yobs  Ycal) of the Pawley ﬁt in the range of
6-34 2q (weighted proﬁle R-factor ¼ 6.68).
Table 1
Summary of Spray Dryer Conditions Tested
Variable Inlet Temperature (K) Pump Rate (%) Solvent
Original spray drying
parameters
393.15 10 Methanol
Condition 1 373.15 10 Methanol
Condition 2 393.15 5 Methanol
Condition 3 373.15 5 Methanol
Condition 4 393.15 10 Ethanol
Figure 1. Calculated XRPD patterns for CBZ I, II, III, and IV compared with the exper-
imental data for spray-dried methanol CBZ solution.
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To support this hypothesis, the diffusion coefﬁcient and drying
rates that are crucial in the formation of CBZ IV by spray drying
were calculated (Eqs. 1-11), with values for each term given in
Table 2. During droplet drying, the diffusivity of CBZ in methanol,
DCBZ/Me, will not only inﬂuence the morphology and structure of
the ﬁnal particles but inﬂuence the nucleation and growth rates
during drying.35 Throughout the drying process, it was assumed
that the droplet liquid was at its wet bulb temperature, Twb.
37 For
drying in N2 or air, the wet bulb temperature can be estimated
from25:
Twb ¼ 137

Tb
373:15
0:68
logðTGÞ  45 (1)
DCBZ/Me was calculated to be 1.101  10
9 m2/s using the
WilkeeChang equation.38,39 Physical properties (viscosity, density,
etc.) of the droplet liquid were taken at Twb.
DCBZ=Me ¼
1:173 10164Me0:5MMe
0:5T
mVCBZ
0:6 (2)
To estimate the evaporation rate, k, of methanol from the
droplets during drying, using (Eq. 3)25
k ¼ 8DMe=N2
rg
rl

YS;MeðTeÞ  Y∞;Me

: (3)
To calculate YS,Me(Te), the equilibrium temperature, Te, was
approximated to thewet bulb temperature, Twb (Eq.1). The saturated
vapor pressure at this temperature was calculated via the Antoine
equation40 to be 0.060 bar. Furthermore, to estimate the mass frac-
tion of methanol at the surface, YS,Me(Te), the mole fraction was ﬁrst
calculated fromDalton’s law (4) before conversion to amass fraction:
YMe ¼
PMe
PT
(4)
Figure 3. Raman spectra for CBZ samples produced under different spray dryer process conditions and a CBZ IV ofﬂine reference.
Figure 4. SEM images of spray-dried CBZ IV. Figure 5. Particle size and size distribution measurements of form IV: CE diameter.
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Therefore, on calculation of Equation 3, the evaporation rate of
methanol during drying is estimated to be 1.024  108 m2/s.
The calculated diffusion coefﬁcient of CBZ and the evaporation
rate can be expressed by the dimensionless Peclet number, Pe, that
calculates the ratio of solvent evaporation to molecular diffusion.41
If the drying process has a Pe < 1, then the diffusion of the solute is
faster than the evaporation rate of the solvent meaning the solute
will diffuse to the core of the droplet and create a solid particle. If
the drying process has a Pe[1, then the diffusion of the solute is
slower than the evaporation of the solvent resulting in shell for-
mation due to enrichment of the solute at the surface of the droplet
creating a hollow particle. For CBZ, the Pe number was calculated
(Eq. 5)25:
Pe ¼
k
8DCBZ=Me
: (5)
To further investigate the possible structural outcome of the
spray-dried CBZ particles, the level of surface enrichment can be
approximated (Eq. 6),25
ECBZ ¼ 1þ
Pe
5
þ
Pe
2
100

Pe
3
4000
: (6)
This equation will indicate the concentration of CBZ at the sur-
face relative to the average concentration of the particle which
would equate to 1.
To determine the process times for spray drying of CBZ, the total
drying time was calculated (Eq. 7)25:
tD ¼
d0
2
k
: (7)
Of the total drying time, a portion of time is required for the
concentration to reach the point crystallization can occur, tsat. First,
the initial supersaturation, S0, can be determined as a ratio of the
initial concentration to the saturated concentration of CBZ in
methanol (Eq. 8)25:
S0 ¼
C0
Csol
: (8)
This value can be used to calculate the time during drying after
which crystallization of CBZ can be possible (Eq. 9)25
tsat ¼ tD

1 ðS0ECBZÞ
2=3

: (9)
It is also important to determine the time in which the process
would need to gain an amorphous form. First, the initial density of
CBZ was determined (Eq. 10)25:
P0 ¼
C0
rt
(10)
Thus, the time required to produce an amorphous solid
(Eq. 11).25
tt ¼ tD

1 ðP0$ECBZÞ
2=3

: (11)
As listed in Table 2, the Pe number calculated from Equation 5
was found to be 1.19. This value of approximately 1 suggests that
CBZ diffuses into the core of the droplet at almost the same rate that
methanol is evaporating. Therefore, an approximately even distri-
bution of CBZ and a solid particle structure would be expected from
the process. Furthermore, the surface enrichment of CBZ, ECBZ, was
found to be 1.254, which shows a low level of surface enrichment.
Given this low value of surface enrichment and the errors associ-
ated with the approximations used in its calculation, it is reason-
able to assume that minimal surface enrichment occurs leading to a
low likelihood of producing a hollow shell particle. This is backed
up by the SEM images in Figure 4, which show isometric and
nonspherical-shaped crystalline particles from the spray drying
process.
Based on the drying rate as calculated earlier, Figure 6 shows the
calculated droplet diameter and CBZ supersaturation within the
droplet throughout the constant rate drying period. This periodwas
found to be 0.061 s, and this is realistic compared with the
approximated drying residence time of the Büchi of 1-1.5 s.34 Of
this total drying period, the ﬁrst 0.0347 s is concerned with the
evaporation of methanol leading to an increase in CBZ concentra-
tion to a supersaturation of 1. After 0.0347 s, crystallization is
feasible but may or may not occur depending on the nucleation
Table 2
Diffusion Coefﬁcient, Evaporation Rate, and Peclet Number Calculation Values
Parameter Value Unit
Methanol boiling point, Tb 337.85 K
Gas outlet temperature, TG 343.15 K
Wet bulb temperature, Twb 279.66 K
Association factor, 4 1.938
Molar volume, VCBZ 0.155
42 m3/kmol
Solvent viscosity, m 7.11  104, 43 N.s/m2
Solvent molecular weight, MMe 32.04 kg/kmol
Droplet temperature, T 279.66 K
Diffusion coefﬁcient, DCBZ/Me 1.101  10
9 m2/s
Diffusion coefﬁcient, DMe=N2 1.10  10
5 m2/s
Drying gas density, rg 1.251 kg/m
3
Droplet liquid density, rl 803.8 kg/m
3
Mass fraction of solvent away from
droplet surface, Y
∞,Me
0
Methanol saturated vapor pressure, PMe 0.060
40 bar
Drying chamber pressure, PT 0.91 bar
Mole fraction methanol at droplet surface, YMe 0.066
Mass fraction methanol at droplet surface, YS,Me(Te) 0.075
Evaporation rate, k 1.024  108 m2/s
Peclet number, Pe 1.19
Surface enrichment, ECBZ 1.254
Droplet diameter, do 25
34 mm
Drying time, tD 0.061 s
Solute initial concentration, C0 0.0104 g/mLMe
Saturated concentration, Csol 0.0460
44 g/mLMe
Initial supersaturation, S0 0.226
Time to crystallization window, tsat 0.0347 s
Solute true density, rt 1.296 g/mL
Initial density, P0 0.008
Time to amorphous concentration, tt 0.0582 s
Figure 6. Droplet diameter and CBZ supersaturation as a function of drying time.
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kinetics. Furthermore, at 0.0582 s if crystallization has not occurred,
the concentration of CBZ will be equal to the true density of solid
CBZ. After this point, an amorphous material can be expected.
When comparing the time to reach the true density with the su-
persaturation curve in Figure 6, the maximum supersaturation
before amorphous formation was found to be S ¼ 34.59. As the
XRPD patterns shown in Figure 1 do not provide any evidence of the
presence of amorphous material, it can be assumed that CBZ
crystallized before this time and supersaturation was reached.
Therefore, it can be concluded that the nucleation kinetics of CBZ
are such that spontaneous nucleation of CBZ IV occurs between
supersaturations of 1 and 34.59.
The ﬁnal step in the formation of CBZ IV is the consideration of
solution-mediated transformation. O'Mahony et al.36 describe the
solution-mediated transformation of CBZ I-III on the scale of mi-
nutes. Based on the previously calculated process times if CBZ IV
nucleated at a supersaturation of 1, particles would only be in
contact with solvent for a further 0.0263 s by which all the solvent
was removed through drying. Therefore, in comparison with the
times detailed,36 solution-mediated transformation to a more sta-
ble form may be unlikely.
To further investigate this supersaturation, evaporation rate and
particle isolation were studied independently out with the dryer.
First in terms of supersaturation, the high inlet temperature used in
the spray dryer will lead to rapid evaporation of solvent from the
surface of the droplets and a rapid rise in supersaturation until
primary nucleation of CBZ occurs. Under high supersaturations,
metastable polymorphs are more likely.16 However, due to the
multiple spray dryer conditions that contribute to supersaturation,
such as feed concentration, drying temperature, drying rate,
droplet diameter, and number, experimental measurement of su-
persaturation in droplets during the process may be unfeasible. In
an attempt to replicate the spray dryer conditions to study super-
saturation, rapid cooling of methanol solutions from 328.15 to
263.15 K of 5 mL was performed in a multi-position crystallization
platform. Samples were monitored for the onset of crystallization
and crystalline samples quickly removed, dried, and analyzed to
identify polymorphic form using XRPD (Fig. 7).
All recrystallized CBZ samples were conﬁrmed as the stable CBZ
III form. Getsoian et al.16 suggest that form II is more likely to be
produced under high supersaturation; however, Sypek et al.45
found that form III was produced when high supersaturations
were exposed to magnetic stirring. This result reinforces the
difﬁculty in obtaining CBZ IV from solution crystallization. This may
be due, however, to a rapid transformation of the initial nucleated
form to the stable CBZ III. To more closely mimic the conditions
within a spray dryer, CBZ methanol solutions were exposed to a
combination of rapid evaporation and solution isolation environ-
ments by spraying solutions onto a heated glass pane. A single glass
pane was heated to 393.15 K using a hot plate, with continuous
spray of CBZ methanol solution introduced to the glass surface. A
suitable mass of powder was achieved in <5 min requiring small
volumes of the sprayed solution and immediately analyzed by
XRPD (Fig. 8).
The sample produced using this rapid evaporation method
comprised a mixture of CBZ IV with a minor component of form I.
This conﬁrms the formation of form IV by rapid drying of solution
out with the spray dryer. The presence of a mixture of CBZ forms in
the glass-sprayed sample is suspected to be due to the lack of solid
removal during continuous spraying. Hence, when the initial
droplets strike the glass and evaporate, the resulting form IV par-
ticles come into contact with further liquid droplets allowing the
transformation to more stable forms. When a thin layer of spray-
dried form IV particles was dispersed on a clean, heated glass
pane at 393.15 K onto which the CBZ methanol solution was
sprayed for roughly 5min. The particles that had been sprayedwith
methanol solution comprised a mixture of CBZ IV, III, and I.
Therefore, the combination of rapid drying and solid isolation in
the spray dryer is an effective means of producing metastable
polymorphs. This highlights the utility of spray drying in the
context of solid-state and polymorph screening experiments as an
effective technique to form and isolate metastable forms that may
not be readily obtained from solution crystallization methods.
Conclusion
Pure CBZ IV has been obtained reproducibly from spray drying
methanol solutions in a commercial spray dryer and by rapid
drying of solutions on a heated plate without the need for addi-
tives. This is in contrast to standard recrystallization methods
from methanol solutions that, even under high supersaturation,
tend to yield more stable forms unless speciﬁc polymeric addi-
tives are used. Rapid supersaturation during evaporation of sol-
vent in the spray dryer (<1 s) promotes the formation of
metastable forms, and continuous isolation of dried particles from
solution inhibits subsequent transformation to more stable forms.
The calculated drying rates and times provide a quantitative
Figure 7. XRPD patterns of varying supersaturations in rapidly cooled methanolic CBZ
solutions.
Figure 8. XRPD of hot plate spray-dried CBZ samples.
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analysis of the time boundaries that govern the crystallization of
metastable polymorphic forms in the spray dryer. The rapid
transformation of form IV in contact with methanol solution
provides an explanation for the failure for many solution recrys-
tallization studies to obtain CBZ IV.
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